Abstract Body

Background

People who inject drugs (PWID) are at risk for HIV infection due to sexual practices and shared injection equipment, but face barriers to accessing pre-exposure prophylaxis (PrEP). Hospitalization for injection drug use (IDU)-related infections may be an opportunity to reduce risk of HIV infection, but data on PrEP interest and preferences in PWID hospitalized with IDU-related infections are limited.

Methods

We conducted a preliminary analysis of data collected in the CHOICE-STAR trial. Eligible participants were adults hospitalized with an IDU-related infection at 4 academic medical centers in the United States. Participants responded to surveys on health, PrEP knowledge, drug use, and sexual practices.

Results

Ninety-two participants were a mean 41 years old, 57 (62%) male, 72 (78%) White, 76 (83%) heterosexual, 13 (14%) uninsured, and 45 (49%) unhoused. In the past 30 days, 71 (77%) participants injected fentanyl/heroin, 37 (40%) cocaine, 19 (21%) methamphetamine, 17 (18%) prescription opioids, and 2 (2%) prescription stimulants. Ten (11%) participants had HIV, including 1 new diagnosis. Of the 82 (89%) participants without HIV, 11 (13%) had previously been offered PrEP, 3 (4%) had used PrEP in the past, and 0 currently used PrEP. Thirty-seven (45%) met CDC criteria for PrEP, including 26 (32%) who met IDU criteria only, 5 (6%) who met sexual criteria only, and 6 (7%) who met both. Overall, 46 (56%) were aware of PrEP and 28 (34%) were interested in taking PrEP, and interest was higher among those who met criteria than those who did not (53% v. 20%; p=.004 by Chi-square). Thirty-one (38%) participants preferred injectable PrEP, 34 (41%) preferred oral, and 17 (21%) stated they would never take PrEP. Of those preferring injectable, 4 (13%) preferred a dosing interval of 1 month, 3 (10%) 2 months, 4 (13%) 6 months, and 20 (65%) 1 year. Of those who prefer oral, 11 (32%) preferred daily pills, 7 (21%) weekly, and 16 (47%) monthly. Forty-three (52%) of HIV-negative participants would prefer if PrEP were available without a prescription.

Conclusions

In this cohort of PWID hospitalized with an IDU-related infection, almost half met CDC criteria for HIV PrEP, but none were currently taking PrEP. Inpatient hospitalization may represent a missed opportunity to engage PWID in PrEP. Inpatient PWID preferred longer dosing intervals and both oral and injectable PrEP. Inpatient PrEP initiation, novel formulations, and longer dosing intervals may help close the gap in HIV prevention for PWID.